Volume 24, Issue 7 (10-2025)
JRUMS 2025, 24(7): 629-642 |
Back to browse issues page
Ethics code: IR.SBMU.RETECH.REC.1402.703
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Bashiri Barazandeh M, Tabesh H, Farzaneh F, Golkar A. In Vitro Study of Curcumin Release from MOF Nanocarrier Based on Metal-Organic Framework Structure and Its Effect on Cancer Cells: A Laboratory Study. JRUMS 2025; 24 (7) :629-642
URL: http://journal.rums.ac.ir/article-1-7694-en.html
URL: http://journal.rums.ac.ir/article-1-7694-en.html
University of Tehran
Abstract: (42 Views)
Background and Objectives: Ovarian cancer is one of the most aggressive malignancies in women, characterized by limited treatment options and drug resistance. Drug nanocarriers can significantly improve the treatment process by enhancing efficacy and reducing toxicity. This study aimed to synthesize and evaluate CUR@ZIF-8 nanoparticles to increase the stability, bioavailability, and selective release of curcumin for ovarian cancer treatment.
Materials and Methods: In this laboratory study, CUR@ZIF-8 nanoparticles were synthesized via a co-precipitation method and characterized using DLS, FE-SEM, FT-IR, UV-Vis, PL, and BET analyses. The release of curcumin was studied at pH 5.5 and 7.4. The anticancer effect of the nanoparticles on A-2780 cells was assessed using the MTT assay over 24 hours.
Results: The particle sizes of ZIF-8 and CUR@ZIF-8 were 135 nm and 196 nm, respectively. The encapsulation efficiency and drug loading were 75% and 9%, respectively. At acidic pH, 90% of the drug was released, while only 25% was released under neutral pH over 196 hours. CUR@ZIF-8 nanoparticles exhibited greater inhibitory effects on cancer cells compared to free curcumin (p<0.0001).
Conclusion: The CUR@ZIF-8 nanoformulation enables controlled and targeted curcumin release and shows a high potential for ovarian cancer therapy. It may also be applicable for the delivery of poorly soluble drugs.
Keywords: Curcumin, Ovarian cancer, pH-sensitive system, Drug delivery, Organic metal nanocarrier
Funding: This study was funded by the Preventative Gynecology Research Center, Shahid Beheshti University of Medical Sciences, under contract number 20-43007996-02.
Conflict of interest: None declared.
Ethical considerations: The Ethics Committee of Shahid Beheshti University of Medical Sciences approved the study (IR.SBMU.RETECH.REC.1402.703).
Authors’ contributions:
- Conceptualization: Hadi Tabesh
- Methodology: Mostafa Bashiri Barazandeh
- Data collection: Mostafa Bashiri Barazandeh
- Formal analysis: Mostafa Bashiri Barazandeh, Ali Golkar
- Supervision: Hadi Tabesh, Farah Farzaneh
- Project administration: Hadi Tabesh, Farah Farzaneh
- Writing – original draft: Mostafa Bashiri Barazandeh
- Writing – review & editing: Mostafa Bashiri Barazandeh, Ali Golkar
Materials and Methods: In this laboratory study, CUR@ZIF-8 nanoparticles were synthesized via a co-precipitation method and characterized using DLS, FE-SEM, FT-IR, UV-Vis, PL, and BET analyses. The release of curcumin was studied at pH 5.5 and 7.4. The anticancer effect of the nanoparticles on A-2780 cells was assessed using the MTT assay over 24 hours.
Results: The particle sizes of ZIF-8 and CUR@ZIF-8 were 135 nm and 196 nm, respectively. The encapsulation efficiency and drug loading were 75% and 9%, respectively. At acidic pH, 90% of the drug was released, while only 25% was released under neutral pH over 196 hours. CUR@ZIF-8 nanoparticles exhibited greater inhibitory effects on cancer cells compared to free curcumin (p<0.0001).
Conclusion: The CUR@ZIF-8 nanoformulation enables controlled and targeted curcumin release and shows a high potential for ovarian cancer therapy. It may also be applicable for the delivery of poorly soluble drugs.
Keywords: Curcumin, Ovarian cancer, pH-sensitive system, Drug delivery, Organic metal nanocarrier
Funding: This study was funded by the Preventative Gynecology Research Center, Shahid Beheshti University of Medical Sciences, under contract number 20-43007996-02.
Conflict of interest: None declared.
Ethical considerations: The Ethics Committee of Shahid Beheshti University of Medical Sciences approved the study (IR.SBMU.RETECH.REC.1402.703).
Authors’ contributions:
- Conceptualization: Hadi Tabesh
- Methodology: Mostafa Bashiri Barazandeh
- Data collection: Mostafa Bashiri Barazandeh
- Formal analysis: Mostafa Bashiri Barazandeh, Ali Golkar
- Supervision: Hadi Tabesh, Farah Farzaneh
- Project administration: Hadi Tabesh, Farah Farzaneh
- Writing – original draft: Mostafa Bashiri Barazandeh
- Writing – review & editing: Mostafa Bashiri Barazandeh, Ali Golkar
|
Citation: Bashiri Barazandeh M, Tabesh H, Farzaneh F, Golkar A. In Vitro Study of Curcumin Release from MOF Nanocarrier Based on Metal-Organic Framework Structure and Its Effect on Cancer Cells: A Laboratory Study. J Rafsanjan Univ Med Sci 2025; 24 (7): 629-42. [Farsi]
|
Type of Study: Research |
Subject:
Pharmacology
Received: 2025/03/14 | Accepted: 2025/08/25 | Published: 2025/10/18
Received: 2025/03/14 | Accepted: 2025/08/25 | Published: 2025/10/18
References
1. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics 2024. CA: A Cancer Journal for Clinicians 2024; 74(1): 12-49.
2. Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics 2025. CA: A Cancer Journal for Clinicians 2025; 75(1): 10.
3. Webb PM, Jordan SJ. Global epidemiology of epithelial ovarian cancer. Nature Reviews Clinical Oncology 2024; 21(5): 389-400.
4. Nguyen NTT, Nguyen TTT, Ge S, Liew RK, Nguyen DTC, Van Tran T. Recent progress and challenges of MOF-based nanocomposites in bioimaging, biosensing and biocarriers for drug delivery. Nanoscale Advances 2024.
5. Wang Y, Zeng M, Fan T, Jia M, Yin R, Xue J, et al. Biomimetic ZIF-8 nanoparticles: a novel approach for biomimetic drug delivery systems. International Journal of Nanomedicine 2024: 5523-44.
6. Parvaneh S, Pourmadadi M, Abdouss M, Pourmousavi SA, Yazdian F, Rahdar A, et al. Carboxymethyl cellulose/starch/reduced graphene oxide composite as a pH-sensitive nanocarrier for curcumin drug delivery. International Journal of Biological Macromolecules 2023; 241: 124566.
7. Rafiee Z, Nejatian M, Daeihamed M, Jafari SM. Application of different nanocarriers for encapsulation of curcumin. Critical Reviews in Food Science and Nutrition 2019; 59(21): 3468-97.
8. Zhang Y, Jia Y, Li M, Hou La. Influence of the 2-methylimidazole/zinc nitrate hexahydrate molar ratio on the synthesis of zeolitic imidazolate framework-8 crystals at room temperature. Scientific Reports 2018; 8(1): 9597.
9. Zheng M, Liu S, Guan X, Xie Z. One-step synthesis of nanoscale zeolitic imidazolate frameworks with high curcumin loading for treatment of cervical cancer. ACS Applied Materials & Interfaces 2015; 7(40): 22181-7.
10. Dawes G, Fratila-Apachitei L, Mulia K, Apachitei I, Witkamp G-J, Duszczyk J. Size effect of PLGA spheres on drug loading efficiency and release profiles. Journal of Materials SCIENCE: Materials in Medicine 2009; 20: 1089-94.
11. Titus D, Samuel EJJ, Roopan SM. Nanoparticle characterization techniques. Green synthesis, characterization and applications of nanoparticles: Elsevier; 2019. p. 303-19.
12. Bahuguna A, Khan I, Bajpai VK, Kang SC. MTT assay to evaluate the cytotoxic potential of a drug. Bangladesh Journal of Pharmacology 2017; 12(2): Online: Apr 8-2017.
13. Cai Y, Guan J, Wang W, Wang L, Su J, Fang L. pH and light‐responsive polycaprolactone/curcumin@ zif‐8 composite films with enhanced antibacterial activity. Journal of Food Science 2021; 86(8): 3550-62.
14. Indira Priyadarsini K. Chemical and structural features influencing the biological activity of curcumin. Current Pharmaceutical Design 2013; 19(11): 2093-100.
15. Butova V, Budnyk A, Bulanova E, Lamberti C, Soldatov A.
16. Hydrothermal synthesis of high surface area ZIF-8 with minimal use of TEA. Solid State Sciences 2017; 69: 13-21.
17. Yin X, Ran S, Cheng H, Zhang M, Sun W, Wan Y, et al. Polydopamine-modified ZIF-8 nanoparticles as a drug carrier for combined chemo-photothermal osteosarcoma therapy. Colloids and Surfaces B: Biointerfaces 2022; 216: 112507.
18. Song Y, Han S, Liu S, Sun R, Zhao L, Yan C. Biodegradable imprinted polymer based on ZIF-8/DOX-HA for synergistically targeting prostate cancer cells and controlled drug release with multiple responses. ACS Applied Materials & Interfaces 2023; 15(21): 25339-53.
19. Peng L, Qiu J, Liu L, Li X, Liu X, Zhang Y. Preparation of PEG/ZIF-8@ HF drug delivery system for melanoma treatment via oral administration. Drug Delivery 2022; 29(1): 1075-85.
20. Zhao H, Gong L, Wu H, Liu C, Liu Y, Xiao C, et al. Development of novel paclitaxel-loaded ZIF-8 metal-organic framework nanoparticles modified with peptide dimers and an evaluation of its inhibitory effect against prostate cancer cells. Pharmaceutics 2023; 15(7): 1874.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
